FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
VELDHOVEN, the Netherlands - ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program.
| Date | Total repurchased shares | Weighted average price | Total repurchased value |
| 11-Dec-17 | 4,000 | 146.13 | 584,508.90 |
| 12-Dec-17 | 55,000 | 147.19 | 8,095,708.28 |
| 13-Dec-17 | 10,000 | 147.19 | 1,471,909.45 |
| 14-Dec-17 | 26,000 | 146.65 | 3,812,995.29 |
| 15-Dec-17 | 100,000 | 145.60 | 14,560,414.40 |
ASML's current share buyback program was announced on 20 January 2016, and details are available on our website at https://www.asml.com/investors/share-buyback/en/s25436
This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).
| Media Relations Contacts | Investor Relations Contacts |
| Monique Mols, phone +31 6 528 444 18 | Skip Miller, phone +1 480 235 0934 |
| Niclas Mika, phone +31 6 201 528 63 | Marcel Kemp, phone +31 40 268 6494 |
